Stock Taper
SCREENER COMPARE ANY 2 STOCKS
IDYA
IDEAYA BIOSCIENCES, INC.
NASDAQ
$40.11
▼ DOWN 3.97% (-1.66)

KEY STATISTICS

Market Cap$3.81 B
52w High$42.68
52w Low$23.23
Dividend Yield—
Frequency—
P/E-20.68
Volume714.06K
Shares Out.95.08M

COMPANY

LEADERSHIP

Yujiro S. Hata
CHIEF EXECUTIVE
Yujiro S. Hata

COMPENSATION 2026

Salary$700,000
Stock Awards$0
Incentive Plan Pay$378,000
All Other Comp.$15,800
Total$9,512,640

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 23, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
145

PRICE TARGET

Target High$63.00
Target Low$48.00
Target Median$60.00
Target Consensus$57.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$9.92M
NOV
9
MON

PRICE

$40.11 ▼ DOWN 3.97% (−$1.66)
$40.00$40.50$41.00$41.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM40.11

About IDEAYA Biosciences, Inc.

https://www.ideayabio.com ↗

IDEAYA Biosciences is a South San Francisco-based precision oncology company developing targeted therapies using synthetic lethality, with lead candidates in clinical trials and collaborations with Pfizer, GSK, and academic institutions.

INDUSTRY

Biotechnology

A PRODUCT IDEAYA BIOSCIENCES, INC. IS KNOWN FOR

Darovasertib
Darovasertib

Darovasertib is an investigational, first-in-class PKC inhibitor in Phase 2/3 trials, developed by IDEAYA as a targeted therapy for uveal melanoma, a rare aggressive eye cancer.

COMPETITORS

COMPETITOR
AURA COMPARE
DCTH COMPARE
IMCR COMPARE
NVS COMPARE
TNGX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Research and Development Services$143.13M $18.72M ▼$155.3M ▲$146.99M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
158
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.00% · 3.0M
XBI
0.86% · 2.5M
XSU.TO
0.11% · 2.1M
SCHA
0.08% · 445.0K
DFAS
0.08% · 284.0K
AVSC
0.25% · 190.1K
FYC
0.43% · 150.0K
CANC
2.70% · 142.3K
FESM
0.07% · 113.2K
SBIO
1.80% · 108.3K
LABU
0.59% · 89.5K
XRS2.F
0.11% · 75.1K
PRFZ
0.09% · 59.1K
RSSL
0.11% · 40.0K
BBSC
0.15% · 26.3K
GSSC
0.07% · 18.5K
RTWP.L
0.26% · 13.8K
BBC
0.86% · 10.8K
TILT
0.01% · 6.0K
RFLR
0.18% · 4.2K
BKSE
0.16% · 3.5K
URTY
0.04% · 3.4K
STXK
0.14% · 3.1K
JF
JFWD
0.90% · 2.7K
VETS
0.13% · 1.3K
TNXT
0.14% · 606

INSTITUTIONAL OWNERSHIP

SHARES OWNED
76.77%
HOLDERS
367
TOP 12 OF 367 · RANKED BY POSITION SIZE
Fmr LLC
14.1M sh · $525.86M
Blackrock, Inc.
8.9M sh · $331.45M
Janus Henderson Group Plc
7.3M sh · $242.02M
Blackrock Inc.
6.8M sh · $239.02M
Capital Research Global Investors
6.6M sh · $178.3M
Vanguard Group Inc
5.0M sh · $173.52M
Baker Bros. Advisors LP
5.0M sh · $186.72M
Federated Hermes, Inc.
4.6M sh · $125.87M
State Street Corp
4.5M sh · $169.54M
Point72 Asset Management, L.P.
3.8M sh · $103.83M
Logos Global Management LP
3.5M sh · $114.95M
Adage Capital Partners Gp, L.L.C.
2.9M sh · $78.91M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF ACCOUNTING OFFICER
Ruiz Briseno Andres
Purchase · 9.6K shares
2026-07-07
★
OFFICER: CHIEF ACCOUNTING OFFICER
Ruiz Briseno Andres
Sale · 9.6K shares
2026-07-07
★
DIRECTOR
Hampton Malcolm Garret
Purchase · 20.0K shares
2026-06-16
★
DIRECTOR
Morrison Scott W
Purchase · 20.0K shares
2026-06-16

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OVERWEIGHT 4
OUTPERFORM 3
NEUTRAL 1
MARKET OUTPERFORM 1
13 GRADES IN THE LAST 12 MONTHS
Wedbush OUTPERFORM Truist Securities BUY RBC Capital OUTPERFORM Mizuho OUTPERFORM Guggenheim BUY Goldman Sachs NEUTRAL Wells Fargo OVERWEIGHT Citigroup BUY

SECTORS PEERS

PEERPRICE
SRRK$57.80COMPARE
KNSA$78.08COMPARE
COGT$34.67COMPARE
ADPT$25.19COMPARE
LEGN$19.88COMPARE
BEAM$29.32COMPARE
ZLAB$26.08COMPARE
MLYS$25.60COMPARE